VAPO News and Press, Vapotherm Inc. From 10/03/22

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages ...

Vapotherm, Inc. (VAPO) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Mark Klausner - Westwicke Partners Joe Army - President and Chief Executive Officer John Landry - Senior Vice President and Chief Financial Officer Conf...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages ...

Vapotherm, Inc. ( NYSE: VAPO ), a high-velocity therapy provider targeting patients with respiratory distress, continues to trade sharply lower after the company reported lower-than-expected 2Q 2022 results that prompted William Blair to downgrade its shares. The analy...

Shares of micro-cap pharmaceutical company Vapotherm ( NYSE: VAPO ) sank 31.3% to $1.76 in Thursday afternoon trading, after the maker of respiratory technology reported Q2 results that missed estimates and slashed its FY 2022 revenue guidance. If the losses hold, VAPO s...

Gainers: InVivo Therapeutics Holdings ( NVIV ) +164% . ChemoCentryx ( CCXI ) +109% . Minerva Neurosciences ( NERV ) +104% . Missfresh ( MF ) +66% . Society Pass ( SOPA ) +49% . Greenpro Capital ( GRNQ ) +48% . Yel...

Gainers: InVivo Therapeutics ( NVIV ) +114% . ChemoCentryx CCXI +108% . GreenLight Biosciences ( GRNA ) +56% . Global Blood Therapeutics GBT +37% . NanoViricides ( NNVC ) +29% . Losers: Helius Medical Technologies ( HSDT...

Vapotherm press release ( NYSE: VAPO ): Q2 GAAP EPS of -$1.61 misses by $0.86 . Revenue of $13M (-37.0% Y/Y) misses by $5.35M . Shares +1.2% . For fiscal 2022, the Company expects net revenue to be in the range of $76 million to $81 million from pr...

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced second quarter 2022 financial results. Second Quarter 2022 Summary Total revenue for the second quarter of 2022 was $13.0 million, a decrease of 37.1% over the second ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings for companies due to report...